---
document_datetime: 2026-01-20 14:10:19
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kostaive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kostaive-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4099438
conversion_datetime: 2026-01-20 20:25:00.698734
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kostaive

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                       |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000284897 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, | 27/11/2025                          |                                             | SmPC and PL                      | SmPC new text Section 4.5 Kostaive may be administered concomitantly with seasonal influenza vaccine. Different injectable vaccines should be |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.5 and 4.8 of the SmPC in order to add information based on final results from study ARCT-2303-01 listed as a category 3 study in the RMP; this is a Phase 3 observer-blind, randomized controlled study to evaluate the immunogenicity, reactogenicity, and safety of Kostaive administered concomitantly with quadrivalent influenza vaccines in adults. The Package Leaflet is updated accordingly. RMP version 2.0 has also been submitted. In addition, the MAH is taking the opportunity   |            |             | given at different injection sites. Section 4.8 Concomitant administration with seasonal influenza vaccine Study ARCT-2303-01 was conducted to evaluate the safety and immunogenicity of a single booster dose of Kostaive co-administered with seasonal influenza vaccine in participants 18 to < 65 years of age (N=403), and 65 years of age and older (N=99). Reactogenicity events were reported at a similar frequency by participants who received Kostaive co-administered with influenza vaccine or Kostaive alone, with no increase in intensity of local or systemic adverse reactions. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000271850 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Update of section 4.8 of the SmPC in order to add Neutrophil count decreased to the list of adverse drug reactions (ADRs) with frequency 'not known' based on the final report from study ARCT-165-01 (NCT05037097) listed as a category 3 study in the RMP. This is a phase 1/2 randomized, observer-blind study of the safety,                                                                                            | 23/10/2025 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                       | reactogenicity, and immunogenicity of 3 SARS-CoV-2 RNA vaccine candidates in adults previously vaccinated and not previously vaccinated against SARS-CoV-2. The Package Leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                                                                                                                                                                    |            |     |             |                                                                                                                                                                                                                            |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000281497 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/07/2025 | N/A |             |                                                                                                                                                                                                                            |
| Variation type II / EMA/VR/0000269728 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to include data based on the final results from study ARCT-154-J01 (jRCT2071220080). This is a Phase 3, randomised, observer-blind, active- controlled, comparative study conducted in Japan to evaluate the safety and immunogenicity of a single dose of ARCT- 154 (ancestral strain) administered intramuscularly to participants aged 18 years or older. In addition, the MAH took the | 24/07/2025 |     | SmPC and PL | SmPC section 5.1. is updated to add data for immune response against SARS-CoV-2 ancestral strain and Omicron BA.4/5 variant up to 12 months. For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

|                                                         | opportunity bring the PI in line with the latest QRD template version 10.4.                                                                      |            |            |                        |
|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000257405 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Arcturus Therapeutics Europe B.V. to Seqirus Netherlands B.V. | 20/03/2025 | 16/04/2025 | SmPC, Labelling and PL |